


**LISTING OF CLAIMS:**

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1. (Currently Amended) A method for treating a host infected with respiratory syncytial virus (RSV) comprising administering to a host in need thereof an anti-RSV effective



amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof,

(I)

wherein:

R<sub>1</sub> is selected from the group consisting of -NHC(O)Y, where Y is C<sub>1</sub>-C<sub>22</sub> alkyl, C<sub>2</sub>-C<sub>22</sub> alkenyl, and C<sub>2</sub>-C<sub>22</sub> alkynyl;

R<sub>2</sub> is selected from the group consisting of -OX, where X is C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, and C<sub>2</sub>-C<sub>5</sub> alkynyl; and

R<sub>3</sub> is phosphocholine.

2. (Previously Presented): The method of claim 1 wherein Y is C<sub>1</sub>-C<sub>14</sub> alkyl, C<sub>2</sub>-C<sub>14</sub> alkenyl, or C<sub>2</sub>-C<sub>14</sub> alkynyl.

3. (Original): The method of claim 1 wherein:


Y is -C<sub>10</sub>H<sub>21</sub>; and

X is -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, or -C<sub>10</sub>H<sub>21</sub>.


4. (Original): The method of claim 1 wherein Y is -C<sub>11</sub>H<sub>23</sub> and X is C<sub>1</sub>-C<sub>5</sub> alkyl.

5. (Previously Presented): The method of claim 1 wherein Y is -C<sub>9</sub>H<sub>19</sub> alkyl.

6. (Previously Presented): The method of claim 1, wherein the compound is



3-dodecanamido-2-ethoxypropyl-1-phosphocholine,




3-decanamido-2-ethoxypropyl-1-phosphocholine,

7. (Original): The method of claim 1 wherein the host is a mammal.

8. (Original): The method of claim 1 wherein the host is a human.

9. (Withdrawn and Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula II:



or a pharmaceutically acceptable salt or prodrugs thereof,

wherein:

M is C<sub>2</sub>-C<sub>4</sub> alkyl;

X<sub>1</sub> is selected from the group consisting of -S-, -O-, -NH-, and -NHC(O)-;

R<sub>21</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> straight chain alkyl, C<sub>2</sub>-C<sub>20</sub> straight chain alkylene containing not more than four double bonds, and aryl;

R<sub>22</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> straight chain alkyl, C<sub>2</sub>-C<sub>20</sub> straight chain alkylene containing not more than four double bonds, and aryl; and

R<sub>23</sub>, R<sub>24</sub>, and R<sub>25</sub> are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, and isopropyl.

10. (Withdrawn): The method of claim 9 wherein

M is -CH<sub>2</sub>CH<sub>2</sub>-;

X<sub>1</sub> is -NHC(O)-;


R<sub>21</sub> is selected from the group consisting of a C<sub>1</sub>-C<sub>16</sub> straight chain alkyl and C<sub>2</sub>-C<sub>16</sub> straight chain alkylene containing not more than one double bond;

R<sub>22</sub> is selected from the group consisting of a C<sub>1</sub>-C<sub>16</sub> straight chain alkyl and C<sub>2</sub>-C<sub>16</sub> straight chain alkylene containing not more than one double bond; and

R<sub>23</sub>, R<sub>24</sub>, and R<sub>25</sub> are each independently hydrogen or methyl.

11. (Withdrawn): The method of claim 9 wherein R<sub>21</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>16</sub> straight chain alkyl and C<sub>2</sub>-C<sub>16</sub> straight chain alkylene containing not more than one double bond; and R<sub>22</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>5</sub> straight chain alkyl and C<sub>2</sub>-C<sub>5</sub> straight chain alkylene containing not more than one double bond.
12. (Withdrawn): The method of claim 11 wherein R<sub>21</sub> is C<sub>9</sub>-C<sub>12</sub> alkyl and R<sub>22</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl.
13. (Withdrawn): The method of claim 11 wherein R<sub>21</sub> is C<sub>9</sub>-C<sub>12</sub> alkyl and R<sub>22</sub> is C<sub>1</sub>-C<sub>5</sub> alkyl.
14. (Withdrawn): The method of claim 11 wherein R<sub>21</sub> is C<sub>9</sub>-C<sub>12</sub> alkyl and R<sub>22</sub> is C<sub>8</sub>-C<sub>12</sub> alkyl.
15. (Withdrawn): The method of claim 9 wherein the host comprises a mammal.
16. (Withdrawn): The method of claim 9 wherein the host comprises a human.

17. (Withdrawn): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula III:



or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

Y is selected from the group consisting of -S-, -O-, -NH-, -N(CH<sub>3</sub>)-, -NHC(O)-, and -N(CH<sub>3</sub>)C(O)-;

R<sub>1</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>2</sub>-C<sub>18</sub> alkenyl, C<sub>2</sub>-C<sub>18</sub> alkynyl, and aryl;

X is a covalent bond or methylene that is optionally substituted with a hydroxyl, C<sub>1</sub>-C<sub>20</sub> alkyl, -O-(C<sub>1</sub>-C<sub>20</sub> alkyl), -S-(C<sub>1</sub>-C<sub>20</sub> alkyl), -C(O)N(C<sub>1</sub>-C<sub>20</sub> alkyl), C<sub>2</sub>-C<sub>20</sub> alkenyl, -O-(C<sub>2</sub>-C<sub>20</sub> alkenyl), -S-(C<sub>2</sub>-C<sub>20</sub> alkenyl), -C(O)N(C<sub>2</sub>-C<sub>20</sub> alkenyl), C<sub>2</sub>-C<sub>20</sub> alkynyl, -O-(C<sub>2</sub>-C<sub>20</sub> alkynyl), -S-(C<sub>2</sub>-C<sub>20</sub> alkynyl), or -C(O)N(C<sub>2</sub>-C<sub>20</sub> alkynyl);

J is a C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted from one to three times with methyl or ethyl; and

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are independently hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

18. (Withdrawn): The method of claim 17 wherein:

Y is -NHC(O)-;

R<sub>1</sub> is C<sub>6</sub>-C<sub>18</sub> alkyl;

X is -C(H)(O-C<sub>1</sub>-C<sub>18</sub> alkyl)- or -C(H)(O-C<sub>1</sub>-C<sub>18</sub> alkenyl)-;

J is -CH<sub>2</sub>CH<sub>2</sub>-; and

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each methyl.

19. (Withdrawn): The method of claim 18 wherein R<sub>1</sub> is -C<sub>11</sub>H<sub>23</sub> and X is -C(H)(O-C<sub>1</sub>-C<sub>5</sub> alkyl)-or -C(H)(O-C<sub>1</sub>-C<sub>5</sub> alkenyl)-


20. (Withdrawn): The method of claim 18 wherein R<sub>1</sub> is -C<sub>9</sub>H<sub>19</sub> and X is -C(H)(OC<sub>2</sub>H<sub>5</sub>)-.

21. (Withdrawn): The method of claim 17 wherein R<sub>1</sub> is -C<sub>9</sub>H<sub>19</sub> and X is -C(H)(OC<sub>10</sub>H<sub>21</sub>)-.

22. (Withdrawn): The method of claim 17 wherein the host comprises a mammal.

23. (Withdrawn): The method of claim 17 wherein the host comprises a human.

24. (Withdrawn and Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula IV:



or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R<sub>1</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>2</sub>-C<sub>18</sub> alkenyl, and C<sub>2</sub>-C<sub>18</sub> alkynyl that is optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amino, or aryl;

X is selected from the group consisting of -NHC(O)-, -N(CH<sub>3</sub>)C(O)-, -C(O)NH-, -C(O)N(CH<sub>3</sub>)-, -S-, -S(O)-, -(SO<sub>2</sub>)-, -O-, -NH-, and -N(CH<sub>3</sub>)-;

R<sub>2</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>14</sub> alkyl, C<sub>2</sub>-C<sub>14</sub> alkenyl, and C<sub>2</sub>-C<sub>14</sub> alkynyl that is optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amino, or aryl;

Y is selected from the group consisting of -NHC(O)-, -N(CH<sub>3</sub>)C(O)-, -C(O)NH-, -C(O)N(CH<sub>3</sub>)-, -S-, -S(O)-, -(SO<sub>2</sub>)-, -O-, -NH-, -N(CH<sub>3</sub>)-, and -OC(O)-;

R<sub>6</sub> is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub> alkyl; C<sub>2</sub>-C<sub>6</sub> alkenyl, and C<sub>2</sub>-C<sub>6</sub> alkynyl; and

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are independently methyl or ethyl, or R<sub>3</sub> and R<sub>4</sub> together form an aliphatic or heterocyclic ring having five or six ring atoms and R<sub>5</sub> is methyl or ethyl.

25. (Withdrawn): The method of claim 24 wherein:

R<sub>2</sub> is C<sub>1</sub>-C<sub>14</sub> alkyl, C<sub>2</sub>-C<sub>14</sub> alkenyl, or C<sub>2</sub>-C<sub>14</sub> alkynyl;

R<sub>6</sub> is -CH<sub>2</sub>CH<sub>2</sub>-; and

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are each independently CH<sub>3</sub>.

26. (Withdrawn): The method of claim 25 wherein R<sub>2</sub> is C<sub>1</sub>-C<sub>5</sub> alkyl or C<sub>2</sub>-C<sub>5</sub> alkenyl.

27. (Withdrawn): The method of claim 25 wherein R<sub>1</sub> is C<sub>8</sub>-C<sub>12</sub> alkyl and R<sub>2</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl.

28. (Withdrawn): The method of claim 25 wherein R<sub>1</sub> is C<sub>8</sub>-C<sub>12</sub> alkyl and R<sub>2</sub> is C<sub>1</sub>-C<sub>5</sub> alkyl.

29. (Withdrawn): The method of claim 25 wherein R<sub>1</sub> is C<sub>8</sub>-C<sub>12</sub> alkyl and R<sub>2</sub> is C<sub>8</sub>-C<sub>12</sub> alkyl.

30. (Withdrawn): The method of claim 27 wherein


X is -NHC(O), -N(CH<sub>3</sub>)C(O)-, -C(O)NH-, -C(O)N(CH<sub>3</sub>); and

Y is -O-, -NH-, or -N(CH<sub>3</sub>)-.

31. (Withdrawn): The method of claim 24 wherein the host comprises a mammal.


32. (Withdrawn): The method of claim 24 wherein the host comprises a human.

33. (Withdrawn): The method of claim 24 wherein the compound comprises:




3-dodecanamido-2-ethoxypropyl-1-phosphocholine.

34. (Withdrawn): The method of claim 24 wherein the compound comprises:



3-decanamido-2-ethoxypropyl-1-phosphocholine.

35. (Withdrawn): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula AA-1:



(AA-1)

or a pharmaceutically acceptable salt thereof,

wherein:

$X^1$  is  $-\text{NHC}(\text{O})-$ ;

$X^2$  is  $-\text{O}-$ ;

R<sup>1</sup> is -C<sub>1</sub>-C<sub>22</sub> alkyl;

R<sup>2</sup> is -C<sub>1</sub>-C<sub>22</sub> alkyl;

R<sup>6</sup> is -CH<sub>2</sub>CH<sub>2</sub>-, and

R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are methyl.

36. (Withdrawn): The method of claim 35, wherein

R<sup>1</sup> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -

CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>, -

(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>12</sub>CH<sub>3</sub> or -(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub>; and

R<sup>2</sup> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -

CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>, -

(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>12</sub>CH<sub>3</sub> or -(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub>.

37. (Withdrawn): The method of claim 36, wherein

R<sup>1</sup> is -(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>; -(CH<sub>2</sub>)<sub>12</sub>CH<sub>3</sub>,

or -(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub>; and

R<sup>2</sup> is CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -

CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>, or -(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>.

38. (Withdrawn): The method of claim 36, wherein

R<sup>1</sup> is -(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, -

(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>, or -(CH<sub>2</sub>)<sub>12</sub>CH<sub>3</sub>; and

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>12</sub>CH<sub>3</sub>, or -(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub>.

39. (Previously Presented): The method of claim 1, wherein the administering is orally, intravenously, parentally, intradermally, subcutaneously, topically, or by inhalation.